Poniard Pharmaceuticals (PARD) 8-K Neorx Reports Second Quarter 2004 Financial Results

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

August 3, 2004

Date of Report (Date of earliest event reported)

NeoRx Corporation

(Exact Name of Registrant as Specified in Charter)

Washington	0-16614	91-1261311
(State or Other Jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

300 Elliot Avenue West, Suite 500, Seattle, WA	98119
(Address of principal executive offices)	(Zip Code)

(206) 281-7001

(Registrant’s telephone number, including area code)

Item 7.    Financial Statements, Pro Forma Financial Information and Exhibits

(c)           Exhibits

99.1         Press Release of NeoRx Corporation, dated August 3, 2004.

Item 12. Results of Operations and Financial Condition

On August 3, 2004, NeoRx Corporation issued a press release announcing its earnings for the three and six months ended June 30, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NeoRx Corporation
Dated: August 4, 2004	By	/s/ Michael K. Jackson
		Michael K. Jackson
		Chief Accounting Officer

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated August 3, 2004

4